Tag: MONOGRAPH

  • Lotiglipron

    Oral nonpeptide small-molecule glucagon-like peptide-1 receptor agonist

    A selective, potent, orally bioavailable small-molecule agonist of the human glucagon-like peptide-1 receptor developed by Pfizer using Sosei Heptares stabilized-receptor technology, advanced through Phase 2 for type 2 diabetes and obesity, and subsequently discontinued owing to hepatic transaminase elevations in a subset of treated participants.

    Abstract

    Lotiglipron (PF-07081532) is an orally administered, nonpeptide, small-molecule agonist of the human glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer in collaboration with Sosei Heptares. The compound was designed through structure-based drug design leveraging Sosei Heptares proprietary StaR (stabilized receptor) technology platform, which enables crystallographic resolution of G-protein-coupled receptor conformations that are otherwise too unstable for conventional structural characterization. Lotiglipron binds within the transmembrane domain of the GLP-1R, activating the Gs-coupled adenylyl cyclase signaling cascade and increasing intracellular cyclic adenosine monophosphate (cAMP) in a manner functionally analogous to the endogenous incretin peptide GLP-1(7-36)amide but with the pharmacokinetic advantages of oral bioavailability, once-daily dosing without fasting requirements, and a plasma elimination half-life of approximately 21 to 27 hours that supports sustained receptor engagement across the dosing interval.

    The compound entered clinical development in 2021 and was advanced through two Phase 1 multiple-ascending-dose studies (Buckeridge et al. 2024) in 74 participants with type 2 diabetes mellitus (T2D) and 26 participants with obesity without diabetes, demonstrating dose-proportional pharmacokinetics across a 10 to 180 mg once-daily dose range, dose-dependent reductions in glycated hemoglobin (HbA1c) of up to 1.61 percentage points at the 180 mg dose over 42 days, and a safety and tolerability profile consistent with the GLP-1R agonist mechanism class. These findings supported advancement to a Phase 2 dose-ranging study (Amin et al. 2025) in 901 participants (512 with T2D, 389 with obesity), which demonstrated statistically significant reductions in HbA1c of up to 1.44 percentage points (80 mg dose, 16 weeks) and body weight reductions of up to 7.47 percent (200 mg dose, 20 weeks). The Phase 2 study included an open-label semaglutide 14 mg comparator arm; lotiglipron at doses above 20 mg produced HbA1c reductions numerically comparable to or exceeding semaglutide at week 16. However, the Phase 2 study was terminated early following identification of hepatic transaminase elevations (alanine aminotransferase and/or aspartate aminotransferase greater than 3 times the upper limit of normal) in 6.0 to 6.6 percent of lotiglipron-treated participants versus 1.6 percent on placebo, with some individuals reaching elevations greater than 8 times the upper limit of normal. No cases of liver failure, symptomatic hepatitis, or Hy’s law were reported. In June 2023, Pfizer announced discontinuation of the lotiglipron clinical program based on the transaminase signal, pharmacokinetic data from Phase 1 drug-drug-interaction studies suggesting impaired hepatic drug transport or metabolism in a subset of participants, and the inability to prospectively identify at-risk individuals.

    Lotiglipron is structurally characterized as a benzimidazole-piperidinyl-benzodioxole derivative bearing a chloropyridinyl substituent and an oxetanylmethyl group (molecular formula C31H31ClN4O5, molecular weight 575.05 g/mol as free base; CAS 2401892-75-7). The compound is not approved in any jurisdiction and is not in active clinical development. Research-grade lotiglipron is available from multiple chemical suppliers and remains a tool compound for the investigation of small-molecule GLP-1R agonist pharmacology, biased signaling, and hepatic metabolism of the oral GLP-1R agonist class. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling, stack interactions, adverse events, and a comparative assessment against five oral or nonpeptide GLP-1R agonist candidates on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1409Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Levobupivacaine

    Plain-language summaryIntrigue 55 / 100

    Levobupivacaine (Chirocaine) is the (S)-enantiomer of bupivacaine, separated out specifically to address the racemate’s cardiotoxicity. Approved by the FDA in 1999. Toxicology comparisons in rat and pig models show 30 to 40 percent lower toxic dose ratios for cardiovascular collapse and seizures than racemic bupivacaine at equivalent neural block efficacy, since the (R)-enantiomer carries most of the cardiac risk through tighter sodium channel binding and slower dissociation. Clinical equivalence trials in epidural, spinal, and peripheral nerve block showed non-inferior efficacy with cleaner CNS toxicity profiles in inadvertent intravascular dosing. Withdrawn from the US market in 2010 for commercial reasons but still available in Europe and Asia. Cost relative to racemic bupivacaine has limited adoption despite the safety advantage. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Amide local anesthetic (S-enantiomer of bupivacaine)

    The (S)-enantiomer of bupivacaine, marketed as Chirocaine, with a reduced cardiotoxic and CNS toxic profile relative to the racemate.

    Abstract

    Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 27262-47-1; molecular formula C18H28N2O; molecular weight 288.43) is the (S)-enantiomer of bupivacaine, developed by Chiroscience and Purdue and approved by the FDA in 1999 (Chirocaine). The enantioselective pharmacology of bupivacaine motivated separation: the (R)-enantiomer carries the dominant cardiotoxic and CNS toxic burden through higher cardiac sodium channel affinity and slower dissociation, while the (S)-enantiomer produces equivalent neural block with substantially reduced toxic margin. Direct toxicology comparisons in rat and pig models show 30 to 40 percent lower toxic dose ratios for cardiovascular collapse and seizure threshold with levobupivacaine versus racemic bupivacaine at equivalent neural block efficacy. Clinical equivalence trials in epidural, spinal, and peripheral nerve block applications demonstrate non-inferior efficacy with lower incidence of CNS toxicity in inadvertent intravascular dosing. Mechanism is identical to racemic bupivacaine (voltage-gated sodium channel block) with the favorable enantioselectivity at cardiac sodium channels driving the safety advantage. Onset, duration, and maximum recommended doses are similar to bupivacaine; some sources permit slightly higher cumulative levobupivacaine doses (3 mg/kg without epinephrine) reflecting the safety margin. The principal limitation of levobupivacaine is acquisition cost relative to racemic bupivacaine, which has restricted uptake in some markets despite the favorable safety profile. The compound was withdrawn from the US market in 2010 for commercial reasons but remains available in Europe and Asia. Lipid emulsion rescue is the standard therapy for any LAST event.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1310Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Survodutide

    GLP-1 and glucagon receptor dual agonist

    A long-acting GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, advanced through Phase 3 in obesity and MASH.

    Abstract

    Survodutide (BI 456906; SAR-441255; CAS 2403761-22-2 mass) is a long-acting GLP-1 receptor and glucagon receptor dual agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. The compound is a 39-residue lipidated peptide based on the glucagon and GLP-1 sequences, with selective potency approximately equivalent at the two receptors and with a fatty acid chain modification enabling once-weekly subcutaneous administration through serum albumin binding (the same pharmacokinetic strategy used by semaglutide, liraglutide, and tirzepatide). The dual-agonist mechanism produces synergistic effects on body weight: GLP-1 receptor agonism reduces appetite and slows gastric emptying through hypothalamic and brainstem pathways (the dominant mechanism shared with semaglutide and other GLP-1 monoagonists), while glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure, mobilizing hepatic and visceral fat in a manner not achieved by GLP-1 monoagonism. Phase 2 obesity results published in 2024 reported up to approximately 19 percent body weight reduction at 46 weeks at the highest dose, similar to the magnitude observed with tirzepatide and substantially greater than semaglutide. The compound is in active Phase 3 development in obesity (SYNCHRONIZE program) and MASH (SYNCHRONIZE-2; metabolic dysfunction-associated steatohepatitis) with anticipated regulatory submissions in 2026 to 2027. Side effect profile parallels other GLP-1-class agents (nausea, vomiting, diarrhea, occasional gastroparesis) with the additional consideration of glucagon-related effects (modest heart rate elevation, occasional hypoglycemia masked by reduced insulin sensitivity, and consideration of bilirubin elevation). Survodutide is distinct from retatrutide (Eli Lilly’s triple GLP-1/GIP/glucagon agonist) in lacking GIP receptor agonism and from cotadutide (AstraZeneca’s GLP-1/glucagon dual) in pharmacokinetic profile and clinical positioning.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1342Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Macimorelin

    Synthetic peptidomimetic growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

    An orally active peptidomimetic ghrelin receptor agonist developed at the University of Montpellier and advanced by Aeterna Zentaris as the first and only approved oral diagnostic test for adult growth hormone deficiency, distinguished from other growth hormone secretagogues by its validated diagnostic application and favorable safety profile relative to the insulin tolerance test.

    Abstract

    Macimorelin (JMV-1843, EP-1572, AEZS-130), a synthetic peptidomimetic agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor), is the first and only orally administered diagnostic agent approved by the United States Food and Drug Administration (December 2017) and the European Medicines Agency (January 2019) for the evaluation of adult growth hormone deficiency (AGHD). The compound was invented and first synthesized at the University of Montpellier and the Centre National de la Recherche Scientifique (CNRS) in France by Fehrentz, Martinez, Guerlavais, and colleagues as part of a structure-activity program seeking orally bioavailable growth hormone secretagogues derived from the hexarelin scaffold, and was subsequently licensed to Aeterna Zentaris for clinical development and marketed under the trade names Macrilen (United States, Novo Nordisk) and Ghryvelin (European Union, Consilient Health and subsequently Pharmanovia) [1, 2]. Structurally, macimorelin is a modified tripeptide containing two indole (tryptophan-derived) moieties linked through a central peptidomimetic backbone with a terminal formamide group and an N-terminal alpha-aminoisobutyric acid cap, conferring oral bioavailability and resistance to proteolytic degradation that distinguish it from the earlier peptide-based growth hormone secretagogues such as GHRP-6 and hexarelin.

    The compound binds the GHS-R1a receptor on pituitary somatotroph cells with an IC50 of 22.9 nanomolar in human pituitary tissue and activates the Gq/11-phospholipase C signaling cascade, stimulating endogenous growth hormone release into the systemic circulation in a manner pharmacologically analogous to the endogenous ligand ghrelin [2, 3]. Following oral administration at the diagnostic dose of 0.5 mg/kg body weight, macimorelin produces a robust and reproducible rise in serum growth hormone concentration that peaks between 30 and 90 minutes post-dose, permitting diagnostic discrimination between growth hormone-sufficient and growth hormone-deficient adults through serial blood sampling over a 90-minute test window. The Phase 3 confirmatory trial (Garcia et al., 2018) in 157 adults demonstrated 87 percent sensitivity and 96 percent specificity at a growth hormone cutoff of 2.8 ng/mL, with 97 percent reproducibility on repeat testing, establishing macimorelin as a clinically validated alternative to the insulin tolerance test with the practical advantages of oral administration, absence of hypoglycemia risk, and a shorter, simpler test protocol [4, 5].

    Pharmacokinetics are characterized by rapid oral absorption (median time to peak plasma concentration approximately 0.75 hours), hepatic metabolism predominantly through cytochrome P450 3A4 (CYP3A4) to a partially active O-demethylated metabolite, a terminal elimination half-life of approximately 4.1 hours, approximately 70 percent plasma protein binding, and predominantly fecal excretion [6, 7]. Food substantially reduces both the rate and extent of absorption (Cmax reduction of approximately 55 percent, AUC reduction of approximately 44 to 49 percent with a high-fat meal), mandating overnight fasting before the diagnostic test. The principal drug interaction concern is with strong CYP3A4 inducers (which may reduce macimorelin exposure and produce false-positive diagnostic results) and strong CYP3A4 inhibitors (which may elevate exposure). The compound produces a mean increase in the corrected QT interval of approximately 11 milliseconds at the diagnostic dose, requiring avoidance of concomitant QT-prolonging medications during the test [8].

    Adverse events in clinical trials were mild and transient, with dysgeusia (bitter or metallic taste), dizziness, headache, nausea, fatigue, hunger, and diarrhea reported at low frequencies. No serious adverse events attributable to macimorelin were reported in the pivotal trials across more than 1000 administered subjects [5, 8]. The compound is administered as a single diagnostic dose rather than as a chronic therapeutic regimen, and the safety profile reflects this acute exposure context. Beyond the diagnostic indication, macimorelin has been investigated in cancer cachexia (pilot trial demonstrating safety and numerical weight improvement) and in pharmacoresistant epilepsy (preclinical seizure suppression through GHS-R1a-mediated neuroprotection), though the compound is not approved for any therapeutic application [9, 10].

    This monograph reviews the chemistry, synthesis, and structural pharmacology of macimorelin; the GHS-R1a receptor mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base across diagnostic and investigational applications; reconstitution and handling considerations; stack interactions and drug-drug interaction considerations; the adverse-event and safety signal; and a comparative assessment of five growth hormone secretagogue or diagnostic candidates (insulin tolerance test, glucagon stimulation test, anamorelin, ibutamoren, and GHRH-arginine test) against macimorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1419Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Ropivacaine

    Plain-language summaryIntrigue 58 / 100

    Ropivacaine (Naropin) is a single-(S)-enantiomer amide local anesthetic approved in 1996, structurally intermediate between mepivacaine (propyl, racemic) and bupivacaine (butyl, racemic). It carries the propyl chain like mepivacaine but the (S)-only purity of the modern enantiopure agents. The shorter alkyl chain reduces lipid solubility versus bupivacaine, producing the so-called motor-sparing profile: at concentrations giving equivalent sensory block, motor block is less profound. That property drives selection in obstetric epidural at low concentrations (0.0625 to 0.125 percent) where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor recovery before discharge matters. Cardiotoxicity profile is favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Maximum dose is 3 mg/kg. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Amide local anesthetic (S-enantiomer propyl analog)

    The (S)-propyl analog of bupivacaine and mepivacaine, marketed as Naropin, with reduced cardiotoxicity and motor-sparing sensory block profile.

    Abstract

    Ropivacaine ((S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 84057-95-4; molecular formula C17H26N2O; molecular weight 274.40) is an amide local anesthetic developed at AB Astra in the 1990s and approved by the FDA in 1996 (Naropin). The compound is structurally intermediate between mepivacaine (propyl chain, racemic) and bupivacaine (butyl chain, racemic): ropivacaine carries the propyl substituent like mepivacaine but is sold as a single (S)-enantiomer. The shorter alkyl chain reduces lipid solubility relative to bupivacaine, contributing to a less profound motor block at concentrations producing equivalent sensory block (the so-called motor-sparing property exploited in obstetric epidural analgesia and ambulatory regional anesthesia). The (S)-enantiomer purity confers a cardiotoxicity profile favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Onset is 5 to 15 minutes for infiltration and peripheral nerve block; duration is 3 to 6 hours, generally somewhat shorter than bupivacaine at equivalent doses. Maximum recommended dose is 3 mg/kg, with cumulative doses up to 770 mg/24 hours documented in continuous epidural analgesia. The motor-sparing profile drives ropivacaine selection in obstetric epidural at low concentrations (0.0625 to 0.125 percent) where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor function recovery before discharge is operationally important. Lipid emulsion rescue applies to any LAST event with ropivacaine as for other long-acting amides.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1311Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • NACET

    Lipophilic ester of N-acetylcysteine and glutathione precursor

    The ethyl ester of N-acetylcysteine, a lipophilic NAC analog with substantially higher cellular and central nervous system bioavailability than the parent acid.

    Abstract

    NACET (N-acetyl-L-cysteine ethyl ester; CAS 59587-09-6; molecular formula C7H13NO3S; molecular weight 191.25) is the ethyl ester prodrug of N-acetylcysteine (NAC), developed at the University of Southern California and at Italian academic groups during the 2000s as a lipophilic alternative to NAC with markedly improved cellular and central nervous system bioavailability. The parent NAC is a polar carboxylic acid with low oral bioavailability (approximately 6 to 10 percent), poor blood-brain barrier penetration, and limited intracellular accumulation; NACET is a neutral ester at physiological pH, crosses cell membranes by passive diffusion, and is hydrolyzed intracellularly by ubiquitous esterases to release NAC inside the cell. Published in vitro studies report cellular glutathione (GSH) elevation 30 to 50 percent above baseline after NACET exposure compared to less than 10 percent for equimolar NAC, owing to the difference in cellular delivery. Published rodent in vivo work reports brain GSH elevation after oral NACET that is not detectable after equimolar oral NAC, consistent with the BBB-penetration argument. The pharmacological consequence is that NACET delivers the antioxidant and glutathione-precursor activity of NAC at lower oral doses with central nervous system exposure. Reported applications in research include neuroprotection, oxidative stress modulation, and as a research tool for cysteine delivery in cell culture. Human pharmacokinetic data are limited and no large clinical trials have been published. The compound is not approved by FDA or EMA for any indication. NAC itself is approved as an antidote for acetaminophen overdose and as a mucolytic; the ester form is sold only as a research-grade compound or supplement. Stability is moderate at room temperature; refrigerated storage is preferred for solid material.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1326Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Orforglipron

    Oral non-peptide GLP-1 receptor agonist (small molecule)

    A small-molecule oral GLP-1 receptor agonist developed by Eli Lilly that does not require absorption of an intact peptide, distinguishing it from the peptide-class oral semaglutide formulation.

    Abstract

    Orforglipron (LY3502970; CAS 2212020-52-3; molecular formula C42H55F3N6O5; molecular weight 781.07) is a small-molecule non-peptide GLP-1 receptor agonist developed by Eli Lilly through licensing of a chemical series originated by Chugai Pharmaceutical and further optimized at Lilly. The compound is the first true small-molecule oral GLP-1 agonist to enter Phase 3 clinical trials; the only previously marketed oral GLP-1 agonist is the peptide-class oral semaglutide (Rybelsus), which requires the SNAC absorption-enhancer formulation and a strict fasted-state administration protocol owing to the intrinsically poor oral bioavailability of peptide GLP-1 agonists. The non-peptide structure of orforglipron eliminates the absorption challenge: oral bioavailability is approximately 30 to 60 percent without absorption enhancers and without strict fasting requirements; the compound is an allosteric agonist that binds at a site distinct from the GLP-1 peptide binding pocket, producing receptor activation through a non-peptide chemical scaffold. Phase 2 obesity results published in 2023 reported approximately 14.7 percent body weight reduction at 36 weeks at the highest dose, comparable to subcutaneous semaglutide and meaningfully greater than oral semaglutide at clinically used doses. Phase 2 type 2 diabetes results showed glycated hemoglobin reduction up to 2.1 percent at the highest dose. The compound is in active Phase 3 development in obesity (ATTAIN program) and type 2 diabetes (ACHIEVE program) with anticipated regulatory submissions in 2025 to 2026. Side effect profile parallels other GLP-1 agonists (nausea, vomiting, diarrhea) with somewhat more rapid onset of adverse events at initiation, attributed to the rapid absorption profile of the small molecule versus the slow titration enabled by long-acting injectable peptides. Orforglipron represents a category-shifting development in the GLP-1 class: oral, simple administration, and competitive efficacy.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1343Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mepivacaine

    Plain-language summaryIntrigue 45 / 100

    Mepivacaine (Carbocaine, Polocaine) is the methyl-substituted parent of the pipecoloxylidide family that includes bupivacaine and ropivacaine. Introduced in the late 1950s by Bo af Ekenstam at AB Bofors. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of its family, with onset in 3 to 5 minutes and duration of 2 to 3 hours. Two niches in current practice: dental anesthesia (the 3 percent plain solution avoids epinephrine when the vasoconstrictor is contraindicated, and the duration matches typical procedure length), and ambulatory orthopedic spinal anesthesia where shorter duration than bupivacaine permits earlier ambulation. Sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine. Lipid emulsion rescue applies as for any local anesthetic systemic toxicity event. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Amide local anesthetic (intermediate-acting)

    The methyl-substituted pipecoloxylidide parent of bupivacaine and ropivacaine, used in dental and orthopedic regional anesthesia.

    Abstract

    Mepivacaine (1-methyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 96-88-8; molecular formula C15H22N2O; molecular weight 246.35) is an amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in the same pipecoloxylidide series that produced bupivacaine and ropivacaine. The compound was introduced clinically in the late 1950s (Carbocaine, Polocaine) as a successor to lidocaine for dental and short-procedure regional anesthesia. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of the pipecoloxylidide family; lipid solubility and protein binding are intermediate between lidocaine and bupivacaine. Mechanism is voltage-gated sodium channel block. Onset is 3 to 5 minutes for infiltration; duration is 2 to 3 hours, longer with epinephrine. Maximum recommended dose is 5 mg/kg without epinephrine and 7 mg/kg with epinephrine. The principal niches in current practice are dental anesthesia (the 3 percent plain solution avoids epinephrine in patients where the vasoconstrictor is contraindicated, and the intermediate duration matches typical dental procedure length), and ambulatory orthopedic spinal anesthesia where the shorter duration relative to bupivacaine permits earlier ambulation and discharge. Mepivacaine is sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine; lipid emulsion rescue applies to LAST. The ester-class procaine and chloroprocaine are alternative short-acting infiltration agents; mepivacaine retains a market niche owing to the absence of the para-aminobenzoic acid metabolite that drives ester allergic reactions.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1312Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • N-PEP-12

    Cerebrolysin-derived oral peptide fraction

    A defined oral peptide fraction prepared from porcine brain tissue, marketed as a nutraceutical analog of intravenous Cerebrolysin for cognitive support.

    Abstract

    N-PEP-12 is a porcine-brain-derived peptide preparation developed by Ever Neuro Pharma (the manufacturer of Cerebrolysin) as a defined orally bioavailable analog of the parent intravenous nootropic. Cerebrolysin itself is a complex hydrolysate of porcine cerebral cortex containing approximately 25 percent free amino acids and 75 percent low-molecular-weight peptides (less than 10 kDa) administered by daily intravenous or intramuscular injection in courses of 10 to 30 days for vascular dementia, Alzheimer’s disease, ischemic stroke recovery, and traumatic brain injury indications across approximately 50 jurisdictions (Europe, Asia, Russia, South America). The intravenous administration is operationally restrictive; N-PEP-12 was developed to provide a similar peptide profile in a daily oral capsule format suitable for outpatient and over-the-counter use. The published characterization describes a peptide molecular weight distribution of 1 to 10 kDa with similar amino acid composition to Cerebrolysin and shared neurotrophic activity in cortical neuron culture (BDNF and IGF-1 mimetic effects, neurite outgrowth, protection against amyloid-beta and glutamate excitotoxicity). Clinical evidence is more limited than for Cerebrolysin: published randomized trials in mild cognitive impairment (MCI) and age-associated memory impairment report modest cognitive improvements over 90 days in single-center studies. The compound is not FDA-approved; it is marketed as a dietary supplement in the United States and as a nutraceutical or medicinal food in European jurisdictions. The principal limitation on the strength of the evidence is the small number of independent clinical trials and the dominance of the manufacturer-sponsored published record. Reconstitution is not required; oral capsules contain approximately 60 mg of peptide blend.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1329Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • SLU-PP-332

    Pan-ERR (estrogen-related receptor) agonist exercise mimetic

    A small-molecule pan-agonist of the three estrogen-related receptor isoforms (ERRฮฑ, ERRฮฒ, ERRฮณ), studied as an exercise mimetic for activation of mitochondrial biogenesis and oxidative metabolism.

    Abstract

    SLU-PP-332 (CAS 2226909-79-9; molecular formula C25H26N2O5S; molecular weight 466.55) is a small-molecule pan-agonist of the estrogen-related receptor (ERR) family of orphan nuclear receptors developed at the Saint Louis University School of Medicine by Thomas Burris and colleagues. The ERR family comprises three isoforms (ERRalpha, ERRbeta, ERRgamma) that share substantial sequence homology with the estrogen receptor but bind distinct ligands and target distinct gene programs; the principal ERR-regulated gene programs include mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and skeletal muscle oxidative fiber phenotype. ERR activity is induced by exercise and is one of the principal transcriptional drivers of the exercise-induced metabolic adaptation phenotype, alongside PGC-1alpha (which is itself an ERR coactivator). SLU-PP-332 was characterized as an inverse partial agonist or full agonist depending on the assay, with similar potency at all three ERR isoforms (EC50 in the low-nanomolar to mid-nanomolar range). Reported in vivo effects in rodent models include increased exercise endurance (treadmill running time approximately doubled in mice receiving the compound at 50 mg/kg subcutaneous daily for several weeks without exercise training), elevation of mitochondrial gene expression in skeletal muscle, reduction of body fat mass on high-fat diet, and protection against age-related muscle dysfunction. The pharmacological profile has motivated interest in the compound as an exercise mimetic for metabolic and aging indications. The compound is research-grade and not approved by any regulatory authority; clinical development through partner companies has been announced but no Phase 1 readouts have been published as of the most recent monograph revision. Reconstitution requires DMSO or co-solvent owing to limited aqueous solubility; storage of solid material at refrigerated or frozen conditions.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1344Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.